



5 February 2007

**PuriCore plc**  
(“PuriCore”)

### **Pre-Close Trading Update**

PuriCore (LSE: PURI), the life sciences company focused on the development and commercialisation of its novel, safe antimicrobial technology, today provides a pre-close trading update prior to publication on 16 April 2007 of its preliminary results for the year ended 31 December 2006. PuriCore’s platform technology mimics the human body’s production of its natural anti-microbial, hypochlorous acid, an entirely safe and non-hazardous approach to disinfection and sterilisation.

PuriCore expects to announce sales for 2006 of approximately \$15.6 million, an increase of 22% over the prior year. The US Food Safety business experienced robust growth during 2006 and now has approximately 1,400 Systems installed in supermarkets across the United States, in line with market expectations. Several substantial new contracts were awarded in 2006, and discussions with other major US grocery retailers continue.

The Endoscopy business, which supplies Sterilox Systems and services for the sterilisation of reusable endoscopes to hospitals, encountered continued challenging conditions as a result of cutbacks in healthcare expenditure in the NHS. Despite these constraints, the installed base of global Endoscopy Systems still grew by more than 20% and year-end customer demand points to a strong start in 2007. Additionally, 100% of existing Endoscopy customers continue to sign new contracts for extended periods, demonstrating a high degree of satisfaction with the Sterilox System and validating PuriCore’s strategy to grow its portfolio of rented Systems.

The combined installed base of PuriCore’s Sterilox Systems in Food Safety and Endoscopy grew over 200% in 2006.

As a result of the NHS spending constraints, operating losses (EBITDA) excluding the impact of non-cash compensation charges for the issuance of stock options and warrants (approximately \$2 million), are expected to be between \$15 – \$16 million for the year, slightly higher than currently forecasted. (Note: Financial ranges provided as full impact of IFRS adjustments not yet finalized.)

PuriCore remains well financed, with cash and cash equivalents at 31 December 2006 of approximately \$43 million.

**Greg Bosch, Chief Executive of PuriCore, said:**

*“PuriCore experienced excellent growth in 2006, tripling the installed base of Sterilox Systems. Importantly, 90% of the 2006 installations were Systems placed under rental agreements, and 78% of our cumulative installed base are under rental contracts at year end, representing \$15 million in future revenue. We continue to expand our rental business which adds to our base of recurring revenue and allows us to plan targeted investments in the future.*

*“Despite a challenging environment for our UK Endoscopy business, we are optimistic that our current backlog of customer demand, coupled with new partnerships to expand our endoscopy portfolio such as the Minntech deal announced today, will enable us to achieve our targets. Similarly, we expect continued robust growth in 2007 in our US Food Safety business.*

*“As we continue to build PuriCore’s global leadership in the field of infection control, we remain focused on delivering strong growth and attractive investment returns to our shareholders. We look forward to sharing more details in the preliminary results on 16 April.”*

**Contacts:**

**PuriCore plc**

Greg Bosch, Chief Executive Officer  
Keith A. Goldan, Chief Financial Officer

**+1 (484) 321-2700**

**Financial Dynamics**

Ben Brewerton  
John Gilbert

**Tel: +44 (0) 20 7831 3113**

**Notes to Editors:**

All financials are unaudited.

PuriCore (LSE: PURI) is a life sciences company focused on the development and commercialisation of its proprietary technology that mimics the production by the human body of its natural anti-microbial, hypochlorous acid. Hypochlorous acid is highly effective at killing pathogens such as bacteria, viruses and fungi and yet is safe and environmentally friendly. PuriCore's solutions have applications in a wide range of markets where it is important to control microbial contamination. These markets include medical device disinfection, food safety, dental equipment decontamination, environmental remediation, hospitality, water safety, wound management and other applications intended to limit the spread of infectious disease, including major global disease threats such as Tuberculosis, MRSA, Influenza, E.coli, Norovirus, HIV, polio, Hepatitis A, H.pylori and Legionella.

PuriCore markets a portfolio of branded systems which produce hypochlorous acid solutions on-site at a customer's location from water, electricity and common salt. These solutions are generated at a range of concentrations and at a nearly neutral pH range similar to the human body. They are effective as soaks, sprays, mists and in other forms.

PuriCore is headquartered in Malvern, Pennsylvania with offices in Stafford, UK.

To receive additional information on PuriCore, please visit our web site at [www.puricore.com](http://www.puricore.com), which does not form part of this press release.